These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32301356)

  • 21. An update and systematic review on drug therapies for the treatment of refractory chronic cough.
    Ryan NM; Vertigan AE; Birring SS
    Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitussive drugs--past, present, and future.
    Dicpinigaitis PV; Morice AH; Birring SS; McGarvey L; Smith JA; Canning BJ; Page CP
    Pharmacol Rev; 2014; 66(2):468-512. PubMed ID: 24671376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATP, an attractive target for the treatment of refractory chronic cough.
    Zhang M; Sykes DL; Sadofsky LR; Morice AH
    Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current and emerging treatment landscape for chronic cough.
    Dicpinigaitis P
    Am J Manag Care; 2022 Sep; 28(9 Suppl):S159-S165. PubMed ID: 36198074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The problem of cough and development of novel antitussives.
    Barnes PJ
    Pulm Pharmacol Ther; 2007; 20(4):416-22. PubMed ID: 17189707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic cough.
    Wee B
    Curr Opin Support Palliat Care; 2008 Jun; 2(2):105-9. PubMed ID: 18685405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing antitussives: the ideal clinical trial.
    Birring SS
    Pulm Pharmacol Ther; 2009 Apr; 22(2):155-8. PubMed ID: 19041729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic cough: future directions in chronic cough: mechanisms and antitussives.
    Chung KF
    Chron Respir Dis; 2007; 4(3):159-65. PubMed ID: 17711916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic management of cough.
    Bolser DC
    Otolaryngol Clin North Am; 2010 Feb; 43(1):147-55, xi. PubMed ID: 20172264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central regulation of the cough reflex: therapeutic implications.
    Canning BJ
    Pulm Pharmacol Ther; 2009 Apr; 22(2):75-81. PubMed ID: 19284972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy for cough: active agents.
    Chung KF; Chang AB
    Pulm Pharmacol Ther; 2002; 15(3):335-8. PubMed ID: 12099788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRPV1 antagonists as potential antitussive agents.
    McLeod RL; Correll CC; Jia Y; Anthes JC
    Lung; 2008; 186 Suppl 1():S59-65. PubMed ID: 17926096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Codeine: A Relook at the Old Antitussive.
    Vora A; Nadkar MY
    J Assoc Physicians India; 2015 Apr; 63(4):80, 82-5. PubMed ID: 26591180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
    Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
    Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Gefapixant, a P2X
    Ishiura Y; Nomura S; Ishii Y; Imai K; Sawai Y; Tamaki T; Shimizu T; Miyashita N; Ito T
    Int Med Case Rep J; 2023; 16():497-501. PubMed ID: 37692174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and future prospects for drugs to suppress cough.
    Chung KF
    IDrugs; 2003 Aug; 6(8):781-6. PubMed ID: 12917774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
    Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
    Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.